ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Medincell SA

Medincell SA (0ACH)

0,00
0,00
( 0,00% )
Mis à jour : -

Medincell SA (0ACH) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
-
( - )
Prix Achat
0,00
Prix Vente
0,00
Volume échangé
427
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
0,00
Ouverture
-
Dernière Transaction
78
@
27.1
(O)
Dernière heure de transaction
10:04:02
Volume financier
-
VWAP
-
Volume moyen (3 m)
108 898 €
Actions en circulation
35 904 117
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-42,37
Bénéfice par action (BPA)
-0,63
Chiffre d'affairess (LTM)
32,44M
Bénéfice net (LTM)
-19,95M

À propos de Medincell SA

MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophreni... MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation in total knee arthroplasty surgery. In addition, its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. It has strategic collaborations with AbbVie to develop, manufacture, and commercialize six long-acting injectable therapeutic products; and IM4TB to develop a long-acting injectable version of Macozinone for the treatment of tuberculosis. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France. Show more

Secteur
-
Industrie
-
Siège social
Jacou, France
Fondé
2026
Medincell SA est coté dans le secteur de la London Stock Exchange avec le ticker 0ACH. Le dernier cours de clôture d'Medincell était de 0,00 €. Au cours de la dernière année, les actions de Medincell ont été négociées dans une fourchette de prix de 0,00 € à 0,00 €.

Medincell compte actuellement 35 904 117 actions en circulation. Medincell a un ratio cours/bénéfice (ratio PE) de -42.37.

0ACH Dernières nouvelles

Aucune actualité à afficher pour le moment.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

0ACH - Frequently Asked Questions (FAQ)

What is the current Medincell SA share price?
The current share price of Medincell SA is 0,00 €
How many Medincell SA shares are in issue?
Medincell SA has 35 904 117 shares in issue
What is the 1 year trading range for Medincell SA share price?
Medincell SA has traded in the range of 0,00 € to 0,00 € during the past year
What is the PE ratio of Medincell SA?
The price to earnings ratio of Medincell SA is -42,37
What is the cash to sales ratio of Medincell SA?
The cash to sales ratio of Medincell SA is 29,71
What is the registered address of Medincell SA?
The registered address for Medincell SA is 3 Rue des Frères Lumière, Jacou, Languedoc-Roussillon, 34830
What is the Medincell SA website address?
The website address for Medincell SA is www.medincell.com

0ACH Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock